Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/Philippines FDA/Gavlin

Approved

STANDARD

Gavlin

J.M. Tolamnn Laboratories Inc.🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: 292c51583e127235
Company: J.M. Tolamnn Laboratories Inc.
Type: Standard

Approval Details

Approval Id: 292c51583e127235
Drug Approval Philippines Name: Gavlin
Product Name: Gavlin
Registration Number: DRP-6278
Brand Name: Gavlin
Generic Name: Guaifenesin + Salbutamol (as sulfate)
Dosage Form: Capsule
Dosage Strength: 100 mg / 2 mg
Manufacturer: J.M. Tolamnn Laboratories Inc.
Issuance Date: 24 September 2022
Expiry Date: 05 October 2027
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

292c51583e127235

Type

Standard

Back to Philippines FDA Approvals

Gavlin - Philippines FDA Drug Approval Details